NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inspire-medical-systems-inc-loss-submission-form/?id=180537&from=3 CLA ...

Core Viewpoint - The article discusses the updated consensus recommendations for the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dressings, emphasizing its evolution into a critical component of surgical care aimed at enhancing patient safety and surgical outcomes [1][6]. Group 1: Overview of ciNPT - ciNPT is designed to manage and protect surgical incisions, particularly for high-risk patients, by applying continuous negative pressure to reduce fluid accumulation and tension on the incision [2]. - A meta-analysis of 84 studies indicates that ciNPT significantly reduces the risk of surgical site complications, dehiscence, skin necrosis, and readmissions compared to standard dressings [2]. Group 2: Recommendations and Guidelines - The panel produced 12 consensus statements based on recent publications and clinical experiences, clarifying the value of ciNPT in surgical practices for at-risk patients [4]. - Risk-based indications suggest that ciNPT is recommended for patients with two or more risk factors, including high-risk incisions and scenarios where delayed healing could affect subsequent therapies [4]. - Area ciNPT dressings are preferred for complex incision geometries, while linear dressings are effective for standard high-tension incisions [4]. Group 3: Integration and Future Directions - ciNPT should be included in surgical site complication prevention protocols for high-risk patients and used alongside validated incision risk scoring systems [4]. - The recommendations aim to standardize practices globally and align with healthcare professionals' priorities for patient safety [5].

PHILADELPHIA, Dec. 17, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company") on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the "Class Period"), inclusive. Investor Deadline: Investors who purchased Integer securities during the Class Period may, no later than February 9 ...

New York, New York--(Newsfile Corp. - December 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - Tandem Diabetes Care, Inc. is a prominent player in the insulin pump technology market, showing resilience against competition from major companies like Medtronic and Insulet Corporation [1] Company Performance - RBC Capital maintains an "Outperform" rating for Tandem Diabetes, raising its price target from $25 to $30, reflecting confidence in the company's growth potential [2] - The average twelve-month price target from brokerages is approximately $22.44, slightly below the current stock price of $23.03, indicating a modest increase of 1.90% or $0.43 [3] Analyst Sentiment - Analyst ratings for Tandem Diabetes show mixed sentiment: one "sell," eleven "hold," and five "buy" recommendations [3] - Stifel Nicolaus initiated coverage with a "hold" rating and a target price of $15.00, while Canaccord Genuity reaffirmed a "buy" rating with a price objective of $24.00 [4] Stock Performance - The stock has fluctuated between a low of $22.40 and a high of $23.10 during the day, with a yearly peak of $38.28 and a low of $9.98 [5] - Tandem Diabetes Care has a market capitalization of approximately $1.56 billion and a trading volume of 120,728 shares on the NASDAQ exchange [5]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its business performance and sales forecasts, leading to significant stock price declines [1][5]. Group 1: Company Performance - On October 23, 2025, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, which was below prior expectations [3]. - The company anticipated net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, indicating a slowdown in growth [3]. - Management revealed that sales of three new products, including two electrophysiology devices, were expected to decline in 2026 due to slower market adoption [3]. Group 2: Stock Impact - Following the announcement of reduced sales guidance, Integer's stock price fell by $35.22 per share, or 32.3%, closing at $73.89 per share on October 23, 2025 [4]. Group 3: Allegations in the Lawsuit - The lawsuit alleges that Integer made materially false and misleading statements about its competitive position in the electrophysiology (EP) manufacturing market [5]. - It is claimed that the company overstated its visibility into customer demand and mischaracterized its EP devices as long-term growth drivers for its Cardio & Vascular segment [5]. - The lawsuit contends that the positive statements made by the company lacked a reasonable basis and were materially misleading [5].

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) between July 25, 2024 through October 22, 2025, inclusive. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Integer Holdings Corporation (NYSE: ITGR)?Did you purchase your shares between Jul ...

Core Viewpoint - STAAR Surgical Company is urging stockholders to participate in the upcoming Special Meeting to vote on the amended agreement with Alcon Inc., emphasizing that the outcome will significantly impact the value of their shares [1]. Company Summary - STAAR Surgical Company is recognized as the global leader in phakic IOLs, specifically with its EVO family of Implantable Collamer® Lenses (EVO ICL™) designed for vision correction [1]. Industry Context - The impending vote at the Special Meeting is positioned as a critical event that could influence the financial performance and stock value of STAAR Surgical, highlighting the importance of shareholder engagement in corporate governance [1].

Carlyle Group has launched a takeover offer for Hogy Medical Co. in the latest private equity-led deal of a Japanese company https://t.co/4SgKSDi7JA ...